CTT Pharmaceuticals Existing Canadian Patent Confirmed to Include Psychedelic Applications ACCESSWIRE Company Advancing Licensing and Partnership Negotiations Patent Applications Accepted in Australia and Jamaica - Grants Anticipated Shortly HAMILTON, ON / ACCESSWIRE / June 15, 2021 / CTT Pharmaceutical Holdings, Inc., (the 'Company' or 'CTT') (OTC PINK:CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, announced today that Canadian law firm Gowlings WLC confirmed that CTT's Canadian patent CA2624110 covering Orally Administrable Wafers applies to all forms of Psychedelic applications. Gowlings legal counsel commented as follows: 'The Canadian patent is quite broad. It is not limited with respect to including any particular pharmaceutical agent and thus… this patent would cover a film including any additional ingredient, including any drug such as a psychedelic drug, cannabinoids, etc.'